Editorial: Insulin glargine and cancer-an unsubstantiated allegation

Diabetes Technology and Therapeutics

Volumn 11, Issue 8, 2009, Pages 473-476

  Garg, Satish K ^a,d   Hirsch, Irl B ^b   Skyler, Jay S ^c  

^a UNIVERSITY OF COLORADO DENVER   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; HUMAN INSULIN; INSULIN GLARGINE; ISOPHANE INSULIN; METFORMIN; SOMATOMEDIN C RECEPTOR; ANTIDIABETIC AGENT; CARCINOGEN; DRUG DERIVATIVE; GLARGINE; INSULIN;

BREAST CANCER; CANCER INCIDENCE; CANCER RISK; COLORECTAL CANCER; DATA BASE; DIABETES CONTROL; DIABETES MELLITUS; DISEASE ASSOCIATION; EDITORIAL; GLYCEMIC CONTROL; HAZARD RATIO; HYPOGLYCEMIA; INSULIN TREATMENT; MEDICAL DECISION MAKING; MONOTHERAPY; MORTALITY; NEOPLASM; PANCREAS CALCIFICATION; PATIENT CARE; PRESCRIPTION; PRIORITY JOURNAL; PROSTATE CANCER; RISK ASSESSMENT; RISK REDUCTION; CHEMICALLY INDUCED DISORDER; HUMAN; METHODOLOGY; PATIENT SELECTION; REPRODUCIBILITY;

CARCINOGENS; DIABETES COMPLICATIONS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; NEOPLASMS; PATIENT SELECTION; REPRODUCIBILITY OF RESULTS; RESEARCH DESIGN;

EID: 69949174459     PISSN: 15209156     EISSN: None     Source Type: Journal    
DOI: 10.1089/dia.2009.1705     Document Type: Editorial

References (27)

1. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ: Overweight, obesity, and mortality from cancer in a prospectively studied cohort of US adults. N Engl J Med 2003; 348:1625-1638.
2. Calle EE, Kaaks R: Overweight, obesity and cancer: Epidemiological evidence and proposed mechanisms. Nat Rev Cancer 2004;4:579-591.
3. Giovannucci E, Michaud D: The role of obesity and related metabolic disturbances in cancers of the colon, prostate and pancreas. Gastroenterology 2007;132:2208-2225.
4. Renehan AG, Roberts DL, Dive C: Obesity and cancer: Pathophysiological and biological mechanisms. Arch Physiol Biochem 2008;114:71-83.
5. Smith GD, Egger M, Shipley MJ, Marmot MG: Postchallenge glucose concentration, impaired glucose tolerance, diabetes, and cancer mortality in men. Am J Epidemiol 1992; 136:1110-1114.
6. Everhart J, Wright D: Diabetes mellitus as a risk factor for pancreatic cancer: A meta-analysis. JAMA 1995;273:1605-1609.
7. Hjalgrim H, Frisch M, Ekbom A, Kyvik KO, Melbye M, Green A: Cancer and diabetes: A follow-up study of two population-based cohorts of diabetic patients. J Intern Med 1997;241:471-475.
8. Hu FB, Manson JE, Liu S, Hunter D, Colditz GA, Michels KB, Speizer FE, Giovannucci E: Prospective study of adult onset diabetes mellitus (type 2) and risk of colorectal cancer in women. J Natl Cancer Inst 1999;91:542-547.
9. Strickler HD, Wylie-Rosett J, Rohan T, Hoover DR, Smoller S, Burk RD, Yu H: The relation of type 2 diabetes and cancer. Diabetes Technol Ther 2001;3:263-274.
10. Coughlin SS, Calle EE, Teras LR, Petrelli J, Thun MJ: Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. Am J Epidemiol 2004;159:1160-1167.
11. Larsson SC, Orsini N, Wolk A: Diabetes mellitus and risk of colorectal cancer: A meta-analysis. J Natl Cancer Inst 2005;97: 1679-1687.
12. Huxley R, Ansary-Moghaddam A, Berrington de Gonzalez A, Barzi F, Woodward M: Type-II diabetes and pancreatic cancer: A meta-analysis of 36 studies. Br J Cancer 2005;92:2076-2083.
13. Larsson SC,Mantzoros CS,Wolk A: Diabetesmellitus and risk of breast cancer: A meta-analysis. Int J Cancer 2007;121:856-862.
14. Jee SH, Ohrr H, Sull JW, Yun JE, Ji M, Samet JM: Fasting serum glucose level and cancer risk in Korean men and women. JAMA 2005;293:194-202.
15. Pisani P: Hyperinsulinaemia and cancer, meta-analyses of epidemiological studies. Arch Physiol Biochem 2008;114: 63-70.
16. Osborne CK, Bolan G, Monaco ME, Lippman ME: Hormone responsive human breast cancer in long-term tissue culture: Effect of insulin. Proc Natl Acad Sci USA 1976;73:4536-4540.
17. Pollak M: Insulin and insulin-like growth factor signaling in neoplasia. Nat Rev Cancer 2008;8:915-928.
18. Smith U, Gale EAM: Does diabetes therapy influence the risk of cancer? Diabetologia 2009; doi: 10.1007/s00125-009-1441- 45.
19. Hemkens LG, Grouven U, Bender R, Günster C, Gutschmidt S, Selke GW, Sawicki PT: Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: A cohort study. Diabetologia 2009; doi 10.1007/ s00125-009-1418-1424
20. Institute for Quality and Efficiency in Health Care: IQWiG Reports-Commission No. A05-03. Long-Acting Insulin Analouges in the Treatment Diabetes Mellitus Type-2 Executive Summary. http://www.iqwig.de/download/A05- 03-Executive-summary-Long-acting-insulin-analogues-in- the-treatment-of- diabetes-mellitus-type-2.pdf (accessed July 3, 2009).
21. Jonasson JM, Ljung R, Talbäck M, Haglund B, Gudbjörnsdottir S, Steineck G: Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden. Diabetologia 2009; doi 10.1007/s00125- 009-1444-1452
22. SDRN Epidemiology Group: Use of insulin glargine and cancer incidence in Scotland: A study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia 2009; doi 10.1007/s00125-009-1447-z.
23. Currie CJ, Poole CD, Gale EAM: The influence of glucoselowering therapies on cancer risk in type 2 diabetes. Diabetologia 2009; doi 10.1007/s00125-009- 1440-6.
24. Rosenstock J, Fonseca V, McGill JB, Riddle M, HalléJP, Hramiak I, Johnston P, Davis M: Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study. http://webcast.easd.org/ press/glargine/download/090940Rosenstockedited.pdf (accessed July 3, 2009).
25. ORIGIN Trial Investigators, Gerstein H, Yusuf S, Riddle MC, Ryden L, Bosch J: Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: The ORIGIN Trial (Outcome Reduction with an Initial Glargine Intervention). Am Heart J 2008;155:26-32, 32.e1-32.e6.
26. Evans JMM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD: Metformin and reduced risk of cancer in diabetic patients. BMJ 2005;330:1304-1305.
27. Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD, Evans JM: New users of metformin are at low risk of incident cancer: A cohort study among people with type 2 diabetes. Diabetes Care 2009 June 29 [Epub ahead of print].